Stentys has raised US$18 million through private equity investment.
Stentys develops a new-generation stent designed for treatment of acute myocardial infarction and coronary artery bifurcations. Based in Princeton, New Jersey, and Paris, France, the company intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure.
Oaklins' team in France advised Stentys on its two financing rounds, raising a total of US$18 million. The team continues to advise Stentys on corporate strategic matters.
Thibaut de Monclin
© Oaklins. All rights reserved. Oaklins refers to Oaklins International Inc. and/or one of its member firms, each of which is a separate legal entity. Please see www.oaklins.com/legal for further details.